Keyword: Novartis

Though the top prize eluded the field, 10 pharma companies racked up gold, silver or bronze Lions for their marketing and advertising efforts.

Pharma entries for Cannes Lions Health honors are at a record low, but a bigger-than-ever group of drugmakers made the short list.

To spur greater uptake of its biosimilars, Novartis' Sandoz has new data supporting switching patients from branded products.

Switzerland's attorney general found no grounds for bribery charges related to Novartis' $1.2 million in payments to Trump attorney Michael Cohen.

We're bringing you some of our favorite conversation snippets that capture the joy, fear and “ho hum” moments that come with running a cancer drugmaker.

Novartis rolled out strong Kisqali data in metastatic breast cancer patients, but whether the results boost the drug depends on how docs decide to follow up.

Pfizer's Xalkori has picked up two FDA breakthrough designations, one for certain lung cancer patients and another in a rare form of lymphoma.  

Contract manufacturer Avara is taking advantage of Sandoz's slimdown efforts by buying a sterile manufacturing plant in Quebec.

The cost of new cancer drug rollouts—$200,000 on average last year—is helping drive treatment costs toward $100 billion annually in the U.S. alone.

AveXis, the gene therapy biotech Novartis snapped up for $8.7 billion, will build a new manufacturing plant to produce its specialized therapies.